HAVCR2 and neoplasm: Specifically, MCs interact with CD8 + T cells and tumor-associated macrophages (TAMs) through the engagement of LGALS9 with T cell immunoglobulin and mucin domain 3 (TIM-3), thereby inhibiting the cytotoxic activity of CD8 + T cells and inducing the secretion of growth factors by TAMs.